In-vitro Diagnostics Market size is predicted to rise from USD 97.36 billion to USD 201.17 billion, exhibiting a CAGR of over 6.1% during the forecast timeline, from 2025 through 2037. In the year 2025, the industry size of in-vitro diagnostics is assessed at USD 102.03 billion.
The market growth is driven by rising demand for PoC and home tests, and laboratory-based tests as these are more dependable due to their higher accuracy. Moreover, increase in hospitalizations that need support from quicker diagnostics will boost the expansion of healthcare infrastructure. As a result, there is a growing need for IVD testing performed in hospitals. Hospitals purchase the majority of IVD equipment and use it extensively. Because IVD tests yield quicker and more precise findings, approximately 6,093 hospitals in the U.S. was predicted to depend constantly on IVD assistance for essential decision-making in 2022.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
6.1% |
Base Year Market Size (2024) |
USD 97.36 billion |
Forecast Year Market Size (2033) |
USD 201.17 billion |
Regional Scope |
|
Product Type (Instruments, Reagents & Consumables)
The instruments segment is predicted to account for largest in-vitro diagnostics market share by 2037, propelled by faster detection of chronic diseases and genetic disorders.
Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology)
The oncology segment is expected to grow substantially during the forecast period, owing to the growing cases of cancer worldwide. According to the WHO data, over 10 million deaths were caused by cancer in 2020.
Our in-depth analysis of the global market includes the following segments:
By Product Type |
|
By Test |
|
By Application |
|
The North America in-vitro diagnostics market is estimated to account for largest share by the end of 2037, driven by increasing requirement of genetic testing for personalized health care, diabetes, and cancer. According to the International Diabetes Federation (IDF), it was estimated that around 32.2 million people in the U.S., were suffering from diabetes in 2021.
The market in the Asia Pacific region is expected to be the fastest-growing during the forecast period, owing to presence of stabilizing economies, the rapid growth of the middle-class population, and rapid urbanization.
Abbott Laboratories received US FDA clearance for the Freestyle libre 2 iOS application for use with compatible iPhones.
Roche Diagnostics launched the Cobas pulse system, a blood glucose management solution with mobile digital health capabilities to improve patient care.
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?